Summary
The primary purpose of the study is to assess safety, and to identify the recommended phase 2
dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to
assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.